RSV Vaccine Race Reduced

The Janssen Pharmaceutical Companies of Johnson & Johnson recently disclosed that after assessing the respiratory syncytial virus (RSV) vaccine landscape, the Company would discontinue its RSV adult vaccine program.

“By periodically refocusing our portfolio, Janssen ensures that we are deeply invested in products that have the power to transform patients’ lives,” said Bill Hait, M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer and Interim Head, Janssen R&D., in a press release on March 29, 2023.

The decision to discontinue the RSV adult vaccine program is part of a broader effort to make strategic choices for its investments to focus on medicines with the greatest potential benefit to patients. 

As of March 31, 2023, the U.S. FDA has not approved any RSV vaccine candidate.

However, the FDA previously approved monoclonal antibody therapies for infants.